---
layout: post
title: "Revocation of Three Authorizations of Emergency Use of In Vitro Diagnostic Devices for Detection and/or Diagnosis of COVID-19; Availability"
date: 2026-02-05 18:55:30 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-09879
original_published: 2023-05-10 00:00:00 +0000
significance: 8.00
---

# Revocation of Three Authorizations of Emergency Use of In Vitro Diagnostic Devices for Detection and/or Diagnosis of COVID-19; Availability

**Published:** February 05, 2026 18:55 UTC
**Source:** Federal Register
**Original Published:** May 10, 2023 00:00 UTC
**Document Number:** 2023-09879

## Summary

The Food and Drug Administration (FDA) is announcing the revocation of the Emergency Use Authorizations (EUAs) (the Authorizations) issued to Thermo Fisher Scientific Inc., for the OmniPATH COVID-19 Total Antibody ELISA Test; Detect, Inc., for the Detect Covid-19 Test; and Cepheid, for the Xpert Xpress SARS-CoV-2/Flu/ RSV. FDA revoked these Authorizations under the Federal Food, Drug, and Cosmetic Act (FD&C Act) as requested by each Authorization holder. The revocations, which include an explanation of the reasons for each revocation, are reprinted at the end of this document.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/05/10/2023-09879/revocation-of-three-authorizations-of-emergency-use-of-in-vitro-diagnostic-devices-for-detection)
- API: https://www.federalregister.gov/api/v1/documents/2023-09879

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
